Literature DB >> 2539980

Cellular tolerance to adenosine receptor-mediated inhibition of lipolysis: altered adenosine 3',5'-monophosphate metabolism and protein kinase activation.

B B Hoffman1, P Prokocimer, J M Thomas, R Vagelos, H Chang, G M Reaven.   

Abstract

Prolonged exposure of many types of cells to drugs or hormones that inhibit the activity of the enzyme adenylate cyclase, such as narcotics and alpha 2-adrenergic agonists, leads to enhanced accumulation of cAMP upon removal of the inhibitory drug. We have found previously that chronic infusion of the adenosine A1 receptor agonist phenylisopropyladenosine (PIA), an inhibitor of adenylate cyclase, into rats leads to enhanced isoproterenol-stimulated cAMP accumulation in adipocytes isolated from these animals. The enhanced cAMP accumulation was associated with an impaired ability of PIA to inhibit lipolysis in these cells. In the present study we have investigated the mechanism of the enhanced cAMP accumulation in adipocytes from PIA-infused rats and the relationship of these changes to the impaired antilipolytic action of the drug. The enhanced isoproterenol-stimulated cAMP accumulation in adipocytes prepared from PIA-infused rats was due to both an increased rate of cAMP synthesis and a decreased rate of cAMP metabolism at high concentrations of cAMP without a change in phosphodiesterase activity. There was heterologous desensitization of the ability of PIA, prostaglandin E1, and nicotinic acid to inhibit cAMP accumulation in the adipocytes from PIA-infused rats; there was an increase in the EC50 of each of these agonists, although maximal inhibition of cAMP accumulation was similar. The relationship between the activation of cAMP-dependent kinase and extent of lipolysis was similar in the two groups of cells. We demonstrated that the explanation for the impaired ability of PIA to decrease the rate of isoproterenol (10(-7) M)-stimulated lipolysis in the cells from the PIA-infused rats was due to the markedly increased concentrations of cAMP in these cells, which led to sufficient activation of the kinase to maintain a high rate of lipolysis even in the presence of PIA. In addition, we found that the changes induced by the PIA infusion were largely reversible over a 2-day period after discontinuing the PIA infusion. These results demonstrate that adipocytes from PIA-infused rats provide an interesting model to investigate the mechanisms of tolerance to inhibitory drugs.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2539980     DOI: 10.1210/endo-124-5-2434

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  6 in total

1.  Tonic activity of the rat adipocyte A1-adenosine receptor.

Authors:  Hui-Xiu Liang; Luiz Belardinelli; Mark J Ozeck; John C Shryock
Journal:  Br J Pharmacol       Date:  2002-03       Impact factor: 8.739

2.  Beta-adrenergic stimulation of adenine nucleotide catabolism and purine release in human adipocytes.

Authors:  H Kather
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

3.  Prolonged infusion of epinephrine down-regulates expression of the fatty acid synthase gene in adipocytes.

Authors:  L Shilo; J H Chin; S Azhar; B B Hoffman
Journal:  Endocrine       Date:  1995-06       Impact factor: 3.633

4.  The effect of calcium removal on the suppression by adenosine of epileptiform activity in the hippocampus: demonstration of desensitization.

Authors:  H Hosseinzadeh; T W Stone
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

5.  Receptor crosstalk: effects of prolonged carbachol exposure on beta 1-adrenoceptors and adenylyl cyclase activity in neonatal rat ventricular myocytes.

Authors:  A Paraschos; J S Karliner
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-09       Impact factor: 3.000

Review 6.  A compendium of G-protein-coupled receptors and cyclic nucleotide regulation of adipose tissue metabolism and energy expenditure.

Authors:  Ryan P Ceddia; Sheila Collins
Journal:  Clin Sci (Lond)       Date:  2020-03-13       Impact factor: 6.876

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.